Latest News

Findings by Sylvester Researchers Point to New Therapeutic Target for Advanced Prostate Cancer

From left, Valeria A. Copello, a graduate student in cancer biology; Dr. Kerry Burnstein; Laine Heidman, a graduate student in pharmacology; and Maria Julia Martinez, Ph.D., a post-doctoral associate at Sylvester.

From left, Valeria A. Copello, a graduate student in cancer biology; Dr. Kerry Burnstein; Laine Heidman, a graduate student in pharmacology; and Maria Julia Martinez, Ph.D., a post-doctoral associate at Sylvester.

The Burnstein lab at Sylvester Comprehensive Cancer Center, along with collaborators at Moffitt Cancer Center and the University of Florida Cancer Center, recently discovered that arginine vasopressin receptor type 1a (AVPR1a) can promote aggressive prostate cancer growth. While arginine vasopressin receptors are normally associated with the regulation of blood pressure and body fluids, the Burnstein lab found that androgen receptor variants, which are one of the mechanisms proposed to underlie prostate cancer relapse, increase levels of AVPR1a in prostate cancer cells.

Their research article, “Arginine vasopressin receptor 1a is a therapeutic target for castration-resistant prostate cancer,” was published June 26 in Science Translational Medicine.

Read more about the research »

More News

Mosquitoes Now a Year-Round Problem in Miami-Dade County, According to Collaborative Research Study

Mosquitoes that can transmit dangerous viruses are now a year-round threat to Miami-Dade County, according to a new study led by University of Miami Miller School of Medicine public health researchers who collaborated with the county’s Mosquito Control Division.

Read more about the study »

A phase III clinical trial evaluating Arimoclomol for the treatment of ALS has reached full enrollment.

Phase III Trial Evaluating Arimoclomol for ALS Patients Reaches Full Enrollment

An international phase III clinical trial evaluating the drug Arimoclomol for the treatment of amyotrophic lateral sclerosis (ALS) has reached full enrollment, as reported by a University of Miami Miller School of Medicine researcher. The current phase III trial builds upon the results of a prior phase II trial that enrolled patients with a rapidly progressive, rare genetic form of ALS.

Read more about the trial »

Dr. Akram Tamer, left, with Dr. Karl Meunch. Video & Photo Gallery

Miller School Celebrates Dr. Akram Tamer’s 50 Years of Inspirational Teaching

Akram Tamer, M.D., came to the University of Miami in 1969 as a resident seeking to advance his knowledge of pediatrics. Through the years, he has cared for young patients and families, conducted significant research and inspired several generations of students, residents and faculty at the Miller School of Medicine through his teaching.

Read more about Dr. Akram Tamer »

From left, Sabita Roy, Ph.D., with first author Li Zhang, M.S. Video & Photo Gallery

Researchers Find Probiotics Can Reduce Morphine Tolerance in Mice

A group of researchers from Sylvester Comprehensive Cancer Center, the Department of Surgery and the Department of Medicine at the University of Miami Miller School of Medicine have found that probiotics can reduce morphine tolerance when used as an adjunct therapy in germ-free mice.

Read more about the research »

Sarah Christensen.

New Vice President for Medical Development and Alumni Relations Announced

Sarah Christensen, a fundraising and development executive with a track record for orchestrating strategic growth in the area of philanthropy, has been named the new vice president for medical development and alumni relations, the University of Miami announced Wednesday.

Read more about Sarah Christensen »

News & Events »

Office of the Dean

A message from the dean

Physician News

Read Med News

e-Update

Read e-Update